Cambium Bio LtdASX: CMB

Quarterly Activities/Appendix 4C Cash Flow Report

Jul 29, 2026 at 6:51 PM EDT · Issued by Cambium Bio Ltd via ASX

Filed with ASX · Jul 29, 2026 at 6:51 PM EDT

On 6ix: 6ix.com/news/quarterly-activitiesappendix-4c-cash-flow-report-751

Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 ASX Announcement 30 July 2026 Quarterly Cashflow Report & Business Update Period ending 30 June 2026 Cambium Bio Limited (ASX:CMB) (Cambium Bio or Company), a...

View Attachment

6ix hasn’t read this filing yet.

Cambium Bio Ltd on 6ix

Earlier from Cambium Bio

Cambium Bio Raises A$1.0 Million via PlacementJul 21
FDA Confirms Single Pivotal Trial Pathway for Elate OcularApr 23
Half Year Report and AccountsFeb 19
Cambium Bio Secures A$2.4 Million Strategic InvestmentJan 19
Cambium Bio Signs Strategic MoU with Benta SASSep 5, 2025

Later from Cambium Bio

Updated Securities Trading PolicyAug 4
Change in Company Secretary and Communication PersonAug 26
FY26 Appendix 4G and Corporate Governance StatementAug 28
FY26 Appendix 4E and Annual ReportAug 28
Proposed issue of securities - CMBAug 31

All Cambium Bio news releases

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio